Acino to buy Mepha businesses in Latin America, Asia; Ranbaxy's $500M reserve wipes out Lipitor gains;

@FiercePharma: Actavis CEO says generics biz "as we know it" is doomed as company launches branded pain drug in U.S. Release | Follow @FiercePharma

> Swiss drugmaker Acino plans to buy the Latin American and Asian businesses from Teva Pharmaceutical Industries' ($TEVA) generics unit Mepha, as part of a deal worth €94 million ($122 million). Report

> Analysts say Ranbaxy Laboratories' $500 million reserve for a settlement with the U.S. Justice Department will more than offset the gains from its exclusive launch of generic Lipitor. News

> Transcept Pharmaceuticals won a $10 million milestone payment from Purdue Pharma for the sleep drug Intermezzo's new listing in the FDA Orange Book. Story

> Dental anesthetic maker Novocol Pharmaceutical is spending about $54 million to upgrade a plant in Ontario, Canada. Release

> Indian officials suggest that the country follow the U.S. and EU in sharing manufacturing inspections, in this case with neighboring countries in Asia and Africa. News

> Miami-based Opko Health is buying the Israeli active pharmaceutical ingredients manufacturer FineTech Pharmaceutical; terms weren't disclosed. Article

Biotech News

@FierceBiotech: More than 1/3 of clinical trials conducted by pharma cos. are now being outsourced, says a Kalorama report. Story  | Follow @FierceBiotech

@JohnCFierce: Proposed "model" plan would restrict portions of sensitive studies to "legitimate scientists." Via WSJNews | Follow@JohnCFierce

@RyanMFierce: Seattle's #biotech scene lacked startup activity in '11 but didn't want for M&A action via @ldtimmerman. Article  | Follow @RyanMFierce

> Roche CEO Schwan outlines drug/diagnostic acquisition strategy. News

> Vivus sinks after delivering oral cleft data on obesity drug ingredient. More

Vaccines News

> Pfizer, GSK to provide more discount vaccines for GAVI. Story

> Oxford researchers find malaria vaccine target. Article

Manufacturing News

> FDA cites Akzo for contamination, leaky equipment. News

> Counterfeiter with Chinese connections is busted. Story

> Daiichi grimaces at Ranbaxy, FDA consent decree. Report

> Trout forges ahead on Novartis-MIT continuous processing effort. Article

And Finally... Mutations in a single gene are associated with rare ovarian, uterine and testicular cancers that previously appeared unrelated, researchers found. Report

Suggested Articles

Talk about making pharma history. Merck's Keytruda has racked up yet another first-of-its-kind approval, this time in a combo with Eisai’s Lenvima.

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.